Paper33170809
Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
Borén J and 14 others. JCI Insight, 2020. Cited by 67 papers, by iCite.
Cite this record
ConductScience Library. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. Papers, record 33170809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33170809
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lipoproteins, VLDL | Major topic |
| Membrane Proteins | Major topic |
| Non-alcoholic Fatty Liver Disease | Major topic |
| Apolipoprotein B-100 | |
| Female | |
| Genetic Predisposition to Disease | |
| Humans | |
| Lipase | |
| Lipid Metabolism | |
| Lipids | |
| Lipoproteins, LDL | |
| Liver | |
| Male | |
| Middle Aged | |
| Polymorphism, Single Nucleotide | |
| Triglycerides |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11369260 | Intracellular assembly of VLDL: two major steps in separate cell compartments. | Trends Cardiovasc Med | 2000 | https://conductscience.org/library/papers/11369260 | PubMed |
| 2 | 24633158 | Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. | Nat Genet | 2014 | https://conductscience.org/library/papers/24633158 | PubMed |
| 3 | 9550550 | SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. | Metabolism | 1998 | https://conductscience.org/library/papers/9550550 | PubMed |
| 4 | 29936596 | Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. | Cell Mol Life Sci | 2018 | https://conductscience.org/library/papers/29936596 | PubMed |
| 5 | 25251399 | Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. | Hepatology | 2015 | https://conductscience.org/library/papers/25251399 | PubMed |
| 6 | 28793795 | Lipid Droplet Biogenesis. | Annu Rev Cell Dev Biol | 2017 | https://conductscience.org/library/papers/28793795 | PubMed |
| 7 | 30098284 | Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. | Horm Mol Biol Clin Investig | 2018 | https://conductscience.org/library/papers/30098284 | PubMed |
| 8 | 23551521 | Ectopic lipid storage and insulin resistance: a harmful relationship. | J Intern Med | 2013 | https://conductscience.org/library/papers/23551521 | PubMed |
| 9 | 16463046 | Overproduction of large VLDL particles is driven by increased liver fat content in man. | Diabetologia | 2006 | https://conductscience.org/library/papers/16463046 | PubMed |
| 10 | 28235613 | Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. | J Hepatol | 2017 | https://conductscience.org/library/papers/28235613 | PubMed |
| 11 | 20821410 | Long-TE 1H MRS suggests that liver fat is more saturated than subcutaneous and visceral fat. | NMR Biomed | 2011 | https://conductscience.org/library/papers/20821410 | PubMed |
| 12 | 32776921 | Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease. | PLoS Genet | 2020 | https://conductscience.org/library/papers/32776921 | PubMed |
| 13 | 19622837 | Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. | J Lipid Res | 2010 | https://conductscience.org/library/papers/19622837 | PubMed |
| 14 | 28867301 | Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. | Cell Metab | 2018 | https://conductscience.org/library/papers/28867301 | PubMed |
| 15 | 8241094 | Influence of triacylglycerol biosynthesis rate on the assembly of apoB-100-containing lipoproteins in Hep G2 cells. | Arterioscler Thromb | 1993 | https://conductscience.org/library/papers/8241094 | PubMed |
| 16 | 15489544 | A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. | J Lipid Res | 2005 | https://conductscience.org/library/papers/15489544 | PubMed |
| 17 | 22878467 | Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. | J Hepatol | 2012 | https://conductscience.org/library/papers/22878467 | PubMed |
| 18 | 15520448 | Relation of the size and intracellular sorting of apoB to the formation of VLDL 1 and VLDL 2. | J Lipid Res | 2005 | https://conductscience.org/library/papers/15520448 | PubMed |
| 19 | 22645248 | The BUME method: a novel automated chloroform-free 96-well total lipid extraction method for blood plasma. | J Lipid Res | 2012 | https://conductscience.org/library/papers/22645248 | PubMed |
| 20 | 29232562 | TM6SF2: A novel target for plasma lipid regulation. | Atherosclerosis | 2018 | https://conductscience.org/library/papers/29232562 | PubMed |
Cited by46
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 67 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42936370 | Hepatic metabolic reprogramming after metabolic and bariatric surgery: Gene-nutrition interactions and precision nutrition. | Obes Pillars | 2026 | https://conductscience.org/library/papers/42936370 | PubMed |
| 42687025 | Molecular mechanisms and pathogenesis of MASH. | Nature | 2026 | https://conductscience.org/library/papers/42687025 | PubMed |
| 42663907 | Waist-to-height ratio as a practical indicator for screening pediatric metabolic dysfunction-associated steatotic liver disease in diverse populations and genetic backgrounds. | World J Pediatr | 2026 | https://conductscience.org/library/papers/42663907 | PubMed |
| 42646265 | Metabolic Rewiring in MASLD: From Disease Mechanisms to Precision Medicine. | Metabolites | 2026 | https://conductscience.org/library/papers/42646265 | PubMed |
| 42529254 | Rethinking the hepatoprotective potential of vegetarian diets in dysfunction-associated steatotic liver disease/metabolic-associated fatty liver disease: a critical narrative review. | Front Nutr | 2026 | https://conductscience.org/library/papers/42529254 | PubMed |
| 42522599 | Autophagy in MASLD: A Metabolic and Precision Medicine Perspective. | Liver Int | 2026 | https://conductscience.org/library/papers/42522599 | PubMed |
| 42241512 | Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease. | Circ Res | 2026 | https://conductscience.org/library/papers/42241512 | PubMed |
| 42051491 | Loss of immunometabolic adaptability in MASH: gut-derived signals drive macrophage reprogramming and fibrosis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42051491 | PubMed |
| 42028921 | Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach. | Kaohsiung J Med Sci | 2026 | https://conductscience.org/library/papers/42028921 | PubMed |
| 42022554 | The therapeutic potential of botanicals: how medicinal plants targeting autophagy can reverse metabolic-associated fatty liver disease. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42022554 | PubMed |
| 41772607 | Genetic modulators of metabolic dysfunction-associated steatotic liver disease (MASLD) and their epistatic interactions: from in vitro and animal models to clinical outcomes. | BMC Med Genomics | 2026 | https://conductscience.org/library/papers/41772607 | PubMed |
| 41310718 | Plasma inflammatory proteome profiles identify MASLD among children with overweight or obesity. | Cardiovasc Diabetol | 2025 | https://conductscience.org/library/papers/41310718 | PubMed |
| 41140757 | Modeling Transmembrane 6 Superfamily Member 2 p.Glu167Lys-associated Steatotic Liver Disease Using Androgen-treated Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells. | Gastro Hep Adv | 2026 | https://conductscience.org/library/papers/41140757 | PubMed |
| 41098801 | Steatotic liver disease and cancer: from pathogenesis to therapeutic targets. | eGastroenterology | 2025 | https://conductscience.org/library/papers/41098801 | PubMed |
| 40955660 | Loss of function of T-box 3 in the liver protects against MASLD. | J Clin Invest | 2025 | https://conductscience.org/library/papers/40955660 | PubMed |
| 40580198 | Meta-Analysis: Effects of Steatotic Liver Disease-Associated Genetic Risk Alleles on Longitudinal Outcomes. | Aliment Pharmacol Ther | 2025 | https://conductscience.org/library/papers/40580198 | PubMed |
| 40239968 | Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease. | Clin Mol Hepatol | 2025 | https://conductscience.org/library/papers/40239968 | PubMed |
| 40166716 | Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease. | Front Physiol | 2025 | https://conductscience.org/library/papers/40166716 | PubMed |
| 39585028 | Metabolic Dysfunction-Associated Steatotic Liver Disease in Chronic Hepatitis C Virus Infection: From Basics to Clinical and Nutritional Management. | Clin Pract | 2024 | https://conductscience.org/library/papers/39585028 | PubMed |
| 39496977 | Rab2A-mediated Golgi-lipid droplet interactions support very-low-density lipoprotein secretion in hepatocytes. | EMBO J | 2024 | https://conductscience.org/library/papers/39496977 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| APOB | 338 | PubTator's text mining | https://conductscience.org/library/genes/338 | NCBI Gene |
| APOC3 | 345 | PubTator's text mining | https://conductscience.org/library/genes/345 | NCBI Gene |
| DNASE2 | 1777 | PubTator's text mining | https://conductscience.org/library/genes/1777 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| PNPLA3 | 80339 | PubTator's text mining | https://conductscience.org/library/genes/80339 | NCBI Gene |
| TM6SF2 | 53345 | PubTator's text mining | https://conductscience.org/library/genes/53345 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33170809
GET https://conductscience.org/api/papers/v1/33170809/references?page=2